Respiratory Syncytial Virus (RSV) Guideline Changes

What is often described as the common cold can be life threatening for small premature babies. Respiratory Syncytial Virus or RSV may only cause a slight cough, watery nasal congestion, and mild fever in older children or adults. In babies that were born very prematurely, RSV causes many more problems. These babies are often sick for weeks, may wheeze for months or years, and can go on to develop chronic lung disease. Many cannot get enough oxygen and must be admitted to the hospital, sometimes even for a week or longer. The sickest of these babies may need to be placed on a breathing machine or heart lung bypass. Some babies with RSV die.

For many years there has been an effective way to significantly decrease the risk of children who were born prematurely becoming sick with RSV.

A prophylaxis therapy that is given monthly during the RSV season to babies who were born prematurely has been approved by the Food and Drug Administration (FDA) with evidence-based guidelines about which babies have been shown to benefit from receiving this medication.

Recently, the American Academy of Pediatrics (AAP) has published new RSV guidelines that significantly limit the recommendations about which babies should receive the medication. 

by the National Coalition for Infant Health

The National Perinatal Association RSV Guidelines supports the FDA-approved indications for this medication and recommend the medication be available for all preterm babies at risk for RSV who have been shown to benefit from its use. Currently the NPA is working on several initiatives to address this issue, including the follow:

    • Revise and update the NPA RSV Guidelines to reflect new data and information about RSV.
    • Share resources for parents and professionals that highlight current information about RSV and how to appeal insurer's decisions to deny access to RSV prophylaxis for a child who is at high risk.
    • Partner with organizations to collaborate on effective ways to educate and inform the public, healthcare providers, payers and policy makers about this issue. 

Learn more about how you can become a member and access what NPA has to offer.

© 2016 National Perinatal Association
Powered by Wild Apricot Membership Software